沙丁胺醇-布地奈德压力定量吸入器治疗轻中度哮喘:DENALI双盲随机对照试验结果
DENALI为3期双盲随机对照试验,纳入≥12岁轻中度哮喘患者,1:1:1:1:1随机接受每日四次沙丁胺醇-布地奈德180/160 μg或180/80 μg、沙丁胺醇180 μg、布地奈德160 μg或安慰剂治疗12周。结果显示两个单组分均对肺功能疗效有贡献,且耐受性良好。
要点
- 沙丁胺醇-布地奈德180/160 μg较布地奈德160 μg显著改善12周FEV1 AUC0-6h。
- 沙丁胺醇-布地奈德180/160和180/80 μg较沙丁胺醇180 μg显著改善第12周谷FEV1。
- 沙丁胺醇-布地奈德耐受性良好,不良事件谱与单组分相似。
核心结论
- 沙丁胺醇和布地奈德两个单组分均对沙丁胺醇-布地奈德复方压力定量吸入器的肺功能疗效有贡献。
- 沙丁胺醇-布地奈德在12周内即使每日规律使用相对较高剂量也耐受良好,无新安全性发现,支持其作为新型缓解治疗。
研究设计与样本
- 3期双盲随机对照试验,纳入≥12岁轻中度哮喘患者,按1:1:1:1:1随机分组。
- 患者接受每日四次沙丁胺醇-布地奈德180/160 μg或180/80 μg、沙丁胺醇180 μg、布地奈德160 μg或安慰剂治疗12周。
- 共随机1001例患者,其中989例≥12岁且可评估疗效。
主要发现
- 12周FEV1 AUC0-6h较基线变化:沙丁胺醇-布地奈德180/160 μg vs 布地奈德160 μg的LSM差异为80.7 mL(95%CI 28.4-132.9),P=.003。
- 第12周谷FEV1较基线变化:沙丁胺醇-布地奈德180/160 μg vs 沙丁胺醇180 μg的LSM差异为132.8 mL(95%CI 63.6-201.9),P<.001。
- 第12周谷FEV1较基线变化:沙丁胺醇-布地奈德180/80 μg vs 沙丁胺醇180 μg的LSM差异为120.8 mL(95%CI 51.5-190.1),P<.001。
- 第1天支气管舒张起效时间和持续时间与沙丁胺醇相似。
- 沙丁胺醇-布地奈德不良事件谱与单组分相似。
关键数值与推荐
- 双主要疗效终点包括12周FEV1 AUC0-6h较基线变化(评估沙丁胺醇效应)和第12周谷FEV1(评估布地奈德效应)。
临床怎么用
- 沙丁胺醇-布地奈德复方压力定量吸入器可作为轻中度哮喘的新型缓解治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the phase 3 MANDALA trial, as-needed albuterol-budesonide pressurized metered-dose inhaler significantly reduced severe exacerbation risk vs as-needed albuterol in patients with moderate-to-severe asthma receiving inhaled corticosteroid-containing maintenance therapy. This study (DENALI) was conducted to address the US Food and Drug Administration combination rule, which requires a combination product to demonstrate that each component contributes to its efficacy. RESEARCH QUESTION: Do both albuterol and budesonide contribute to the efficacy of the albuterol-budesonide combination pressurized metered-dose inhaler in patients with asthma? STUDY DESIGN AND METHODS: This phase 3 double-blind trial randomized patients aged ≥ 12 years with mild-to-moderate asthma 1:1:1:1:1 to four-times-daily albuterol-budesonide 180/160 μg or 180/80 μg, albuterol 180 μg, budesonide 160 μg, or placebo for 12 weeks. Dual-primary efficacy end points included change from baseline in FEV1 area under the curve from 0 to 6 h (FEV1 AUC0-6h) over 12 weeks (assessing albuterol effect) and trough FEV1 at week 12 (assessing budesonide effect). RESULTS: Of 1,001 patients randomized, 989 were ≥ 12 years old and evaluable for efficacy. Change from baseline in FEV1 AUC0-6h over 12 weeks was greater with albuterol-budesonide 180/160 μg vs budesonide 160 μg (least-squares mean [LSM] difference, 80.7 [95% CI, 28.4-132.9] mL; P = .003). Change in trough FEV1 at week 12 was greater with albuterol-budesonide 180/160 and 180/80 μg vs albuterol 180 μg (LSM difference, 132.8 [95% CI, 63.6-201.9] mL and 120.8 [95% CI, 51.5-190.1] mL, respectively; both P < .001). Day 1 time to onset and duration of bronchodilation with albuterol-budesonide were similar to those with albuterol. The albuterol-budesonide adverse event profile was similar to that of the monocomponents. INTERPRETATION: Both monocomponents contributed to albuterol-budesonide lung function efficacy. Albuterol-budesonide was well tolerated, even at regular, relatively high daily doses for 12 weeks, with no new safety findings, supporting its use as a novel rescue therapy. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT03847896; URL: www. CLINICALTRIALS: gov.
引用
- Chipps, Israel, Beasley, et al. Albuterol-Budesonide Pressurized Metered Dose Inhaler in Patients With Mild-to-Moderate Asthma: Results of the DENALI Double-Blind Randomized Controlled Trial. Chest. 2023. PMID: 37003355. doi:10.1016/j.chest.2023.03.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。